Data / Form D filings / Voltron Therapeutics, Inc.
Voltron Therapeutics, Inc.: Form D filings
Voltron Therapeutics, Inc., a biotechnology company in New York, NY, filed 5 Form D notices with the SEC between 2021 and 2023. The latest, on November 9, 2023, reports $3.2 million sold of an offering with no set size to 63 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 12 E 49TH STREET, 11TH FLOOR, New York, NY, 10017
- Phone
- (646) 335-5923
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1835742
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 9, 2023 | Amendment | Indefinite | $3,210,680 | 63 | Oct 28, 2022 | sec.gov | |
| Nov 9, 2022 | New notice | Indefinite | $515,000 | 8 | Oct 28, 2022 | sec.gov | |
| Jun 16, 2022 | New notice | $5,000,000 | $300,000 | $4,700,000 | 1 | Jun 3, 2022 | sec.gov |
| Sep 1, 2021 | New notice | $12,000,000 | $2,502,011 | $9,497,989 | 36 | Aug 19, 2021 | sec.gov |
| Jul 13, 2021 | New notice | $3,349,428 | $3,349,428 | 49 | Oct 31, 2019 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Matthew Eitner | Director | |
| Paul Korner | Director | |
| James Ahern | Director | |
| Anthony Zook | Director | |
| Matthew Duffy | Executive Officer, Director | |
| Patrick Gallagher | Executive Officer, Director |
Other biotechnology companies in New York that filed recently
- Swep Bio, Inc. $2.5 million · Oct 29, 2026
- Hypercell Technologies Inc. $3 million · Oct 14, 2026
- CAD Therapeutics, Inc. $4 million · Oct 2, 2026
- Vicora, Inc. $2.3 million · Sep 18, 2026
- GevRx Nutraceuticals, Inc. $300,000 · Sep 18, 2026
- Episteme Prognostics, Inc. $5.1 million · Sep 4, 2026
Every Form D from the week of Nov 6, 2023 · All recent filings in New York · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Voltron Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.